HomeMOLN • NASDAQ
add
Molecular Partners AG
Nakaraang pagsara
$4.01
Sakop ng araw
$3.84 - $4.07
Sakop ng taon
$3.36 - $5.36
Market cap
163.07M USD
Average na Volume
3.44K
P/E ratio
-
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (CHF) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 4.48M | -16.15% |
Net na kita | -12.65M | -12.62% |
Net profit margin | — | — |
Kita sa bawat share | -0.36 | -20.00% |
EBITDA | -12.44M | 14.47% |
Aktuwal na % ng binabayarang buwis | -0.03% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CHF) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 93.06M | -37.73% |
Kabuuang asset | 102.11M | -35.59% |
Kabuuang sagutin | 21.77M | 28.90% |
Kabuuang equity | 80.33M | — |
Natitirang share | 37.41M | — |
Presyo para makapag-book | 1.86 | — |
Return on assets | -29.56% | — |
Return on capital | -34.98% | — |
Cash Flow
Net change in cash
| (CHF) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -12.65M | -12.62% |
Cash mula sa mga operasyon | -11.15M | 15.49% |
Cash mula sa pag-invest | 11.95M | 365.95% |
Cash mula sa financing | -300.00K | -101.96% |
Net change in cash | 294.00K | 115.65% |
Malayang cash flow | -6.65M | -4.92% |
Tungkol
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Itinatag
2004
Website
Mga Empleyado
134
